<DOC>
	<DOCNO>NCT01402180</DOCNO>
	<brief_summary>A randomized phase II tials study whether 's benefit add Nimotuzumab chemoradiation patient esophageal squamous cell carcinoma radical esophagectomy suffer locoregional lymph node recurrence .</brief_summary>
	<brief_title>Chemoradiation With Without Nimotuzumab Treating Esophageal Cancer Patients Who Suffer With Recurrence Regional Lymph Nodes After Esophagectomy</brief_title>
	<detailed_description>Patient population : Esophageal squamous cell carcinoma radical esophagectomy , recurrent lymph node bilateral supravascular fossa upper mediastinum 6 month beyond esophagectomy . Scheme : Eligible recurrent patient esophageal cancer first stratify recurrent time esophagectomy ( within 2 year esophagectomy , beyond 2 year esophagectomy ) , randomize 2 arm 1:1 ratio . Arm A : Chemoradiation + weekly Nimotuzumab 6 week concurrent radiation . Arm B : Chemoradiation .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>1 . Age ≥ 18 ≤75 2 . ECOG performance status 02 3 . Histologically proven primary thoracic esophageal squamous cell carcinoma 4 . Diagnosis regional lymph node ( biosupravascular fossa upper mediastinum ) recurrence radical esophagectomy , base pathological find image show lymph node enlargement 5 . Period esophagectomy diagnosis regional lymph node recurrence 6 month 6 . Without prior radiotherapy 7 . Weight loss 10 % past 6 month 8 . WBC≥ 4.0X109/L , Absolute neutrophil count ( ANC ) ≥ 2.0X109/L 9 . Platelets ≥ 100X109/L 10 . Hemoglobin ≥ 90g/L ( without blood transfusion ) 11 . AST ( SGOT ) /ALT ( SGPT ) ≤ 2.5 x upper limit normal , Bilirubin ≤ 1.5 x upper limit normal 12 . Creatinine ≤ 1.5 x upper limit normal 13 . Sign studyspecific inform consent prior study entry 1 . With recurrence metastasis regional lymph node ( biosupravascular fossa upper mediastinum ) 2 . Prior invasive malignancy ( except nonmelanomatous skin cancer ) unless disease free minimum 2 year ( For example , carcinoma situ breast , oral cavity , cervix permissible ) . 3 . Severe , active comorbidity , define follow : 3.1 Unstable angina and/or congestive heart failure require hospitalization within last 3 month 3.2 Transmural myocardial infarction within last 6 month 3.3 Acute bacterial fungal infection require intravenous antibiotic time registration 3.4 Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization preclude study therapy time registration 3.5 Acquired immune deficiency syndrome ( AIDS ) base upon current CDC definition ; note , however , HIV test require entry protocol . The need exclude patient AIDS protocol necessary treatment involve protocol may significantly immunosuppressive . 4 . Pregnancy woman childbearing potential men sexually active willing/able use medically acceptable form contraception . 5 . Prior radiation therapy prior target drug therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>Esophageal squamous cell carcinoma</keyword>
	<keyword>lymph node recurrence</keyword>
	<keyword>chemoradiation</keyword>
	<keyword>Nimotuzumab</keyword>
</DOC>